PNC Financial Services Group’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39 | Hold |
23
| – | – | ﹤0.01% | 5181 |
|
|
2026
Q1 | $30 | Hold |
23
| – | – | ﹤0.01% | 5142 |
|
|
2025
Q4 | $43 | Hold |
23
| – | – | ﹤0.01% | 5105 |
|
|
2025
Q3 | $29 | Hold |
23
| – | – | ﹤0.01% | 5053 |
|
|
2025
Q2 | $29 | Sell |
23
-346
| -94% | -$400 | ﹤0.01% | 4879 |
|
|
2025
Q1 | $435 | Sell |
369
-712
| -66% | -$1.09K | ﹤0.01% | 4667 |
|
|
2024
Q4 | $1.98K | Buy |
1,081
+1,019
| +1,644% | +$1.99K | ﹤0.01% | 4285 |
|
|
2024
Q3 | $105 | Sell |
62
-580
| -90% | -$953 | ﹤0.01% | 4720 |
|
|
2024
Q2 | $880 | Sell |
642
-1,362
| -68% | -$2.75K | ﹤0.01% | 4451 |
|
|
2024
Q1 | $7.51K | Buy |
2,004
+1,771
| +760% | +$10.4K | ﹤0.01% | 3845 |
|
|
2023
Q4 | $2.29K | Buy |
233
+169
| +264% | +$1.38K | ﹤0.01% | 4168 |
|
|
2023
Q3 | $534 | Sell |
64
-164
| -72% | -$1.87K | ﹤0.01% | 4451 |
|
|
2023
Q2 | $3.03K | Buy |
228
+164
| +256% | +$1.99K | ﹤0.01% | 4249 |
|
|
2023
Q1 | $742 | Hold |
64
| – | – | ﹤0.01% | 4478 |
|
|
2022
Q4 | $524 | Hold |
64
| – | – | ﹤0.01% | 4523 |
|
|
2022
Q3 | $0 | Hold |
64
| – | – | ﹤0.01% | 4567 |
|
|
2022
Q2 | $0 | Sell |
64
-172
| -73% | -$1.04K | ﹤0.01% | 4656 |
|
|
2022
Q1 | $2K | Sell |
236
-9,168
| -97% | -$106K | ﹤0.01% | 4219 |
|
|
2021
Q4 | $192K | Sell |
9,404
-182
| -2% | -$4.39K | ﹤0.01% | 2277 |
|
|
2021
Q3 | $245K | Buy |
9,586
+88
| +0.9% | +$2.61K | ﹤0.01% | 2058 |
|
|
2021
Q2 | $331K | Sell |
9,498
-1,533
| -14% | -$44.6K | ﹤0.01% | 1901 |
|
|
2021
Q1 | $368K | Buy |
11,031
+10,983
| +22,881% | +$384K | ﹤0.01% | 1787 |
|
|
2020
Q4 | $1K | Buy |
+48
| New | +$816 | ﹤0.01% | 3913 |
|
|
2016
Q3 | – | Sell |
-380
| Closed | -$3K | – | 4198 |
|
|
2016
Q2 | $3K | Sell |
380
-14
| -4% | -$128 | ﹤0.01% | 4049 |
|
|
2016
Q1 | $3K | Buy |
394
+14
| +4% | +$138 | ﹤0.01% | 4061 |
|
|
2015
Q4 | $5K | Hold |
380
| – | – | ﹤0.01% | 3869 |
|
|
2015
Q3 | $1K | Buy |
380
+13
| +4% | +$64 | ﹤0.01% | 4480 |
|
|
2015
Q2 | $2K | Buy |
367
+168
| +84% | +$972 | ﹤0.01% | 4420 |
|
|
2015
Q1 | $1K | Hold |
199
| – | – | ﹤0.01% | 4505 |
|
|
2014
Q4 | $2K | Hold |
199
| – | – | ﹤0.01% | 3812 |
|
|
2014
Q3 | $1K | Hold |
199
| – | – | ﹤0.01% | 3849 |
|
|
2014
Q2 | $1K | Hold |
199
| – | – | ﹤0.01% | 3696 |
|
|
2014
Q1 | $1K | Buy |
+199
| New | +$1.26K | ﹤0.01% | 3697 |
|
Other funds holding PACB
AIM
NAMA
PNC Financial Services Group's PACB Position: Q2 2026 in Review
PNC Financial Services Group held its Pacific Biosciences (PACB) position steady in Q2 2026 at 23 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #5181.
PNC Financial Services Group first reported a position in PACB in Q1 2014 and has held it in 33 quarters since. The position peaked at $368K in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- PNC Financial Services Group held 23 shares of Pacific Biosciences worth $39 as of Q2 2026.
- PNC Financial Services Group left its Pacific Biosciences share count unchanged in Q2 2026.
- Pacific Biosciences made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5181 holding.
- PNC Financial Services Group first reported a position in Pacific Biosciences in Q1 2014 and has held it in 33 quarters since.
- PNC Financial Services Group's Pacific Biosciences position peaked at $368K in Q1 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.